TOP1 and neoplasm: Here this group proposes a dose-escalation strategy integrating tumor-targeted TOP1 inhibitor with optimized PARP inhibitor scheduling, and evaluate the safety and efficacy in a phase 1 trial of 24 patients with advanced solid tumors.